Therapeutic Infliximab antibody from the original Remicade® commercial drug.
Product batch | Expiry date | Brand & Origin | Price | 1. Select quantity range | 2. Your quantity | |
---|---|---|---|---|---|---|
2019.11 |
Remicade® DE |
102,00 €
/mg
|
Select quantity: Max: 20
Min: 4
Step: 2
|
Max: 20
Min: 4
Step: 2
|
||
2019.08 |
Remicade® DE |
102,00 €
/mg
|
Select quantity: Max: 20
Min: 4
Step: 2
|
Max: 20
Min: 4
Step: 2
|
||
2020.02 |
Remicade® DE |
102,00 €
/mg
|
Select quantity: Max: 20
Min: 4
Step: 2
|
Max: 20
Min: 4
Step: 2
|
||
2021.03 |
Remicade® DE |
102,00 €
/mg
|
Select quantity: Max: 20
Min: 4
Step: 2
|
Max: 20
Min: 4
Step: 2
|
||
2020.12 |
Remicade® DE |
102,00 €
/mg
|
Select quantity: Max: 20
Min: 4
Step: 2
|
Max: 20
Min: 4
Step: 2
|
Product batch | Expiry date | Brand & Origin | Price | 1. Select quantity range | 2. Your quantity | |
---|---|---|---|---|---|---|
Date to be defined |
Remsima® DE |
120,00 €
/mg
|
Select quantity: Max:
Min: 20
Step: 2
|
Max:
Min: 20
Step: 2
|
||
2025.01 |
Flixabi® DE |
119,50 €
/mg
|
Select quantity: Max: 20
Min: 4
Step: 2
|
Max: 20
Min: 4
Step: 2
|
||
2027.03 |
Inflectra® |
90,00 €/mg
|
Max: 78
Min: 1
Step: 1
|
|||
2022.10 |
Zessly® DE |
120,50 €
/mg
|
Select quantity: Max: 20
Min: 4
Step: 2
|
Max: 20
Min: 4
Step: 2
|
Evidentic’s analytical service includes a comprehensive array of methods to support the drug development process, including, for example, structure, aggregation, degree of isomerization and N-glycans identification of the active pharmaceutical ingredient (API).
Here you will find the product information for the reference product.
Drug name | Remicade® |
INN | Infliximab |
API type | Infliximab is a chimeric human-murine IgG1 monoclonal antibody produced in murine hybridoma cells by recombinant DNA technology. After reconstitution each ml contains 10 mg of infliximab. |
Pharmacotherapeutic group | tumour necrosis factor alpha (TNFα) inhibitors |
ATC code | L04AB02 |
Target of antibody | TNF-α; Synonyms: DIF, TNF-alpha, TNFA, TNFSF2, RATTNF, Tnfa, tnf, TNF-a, TNFalpha, Tnfsf1a, TNFa, cTNF, Tnf-alpha, tnfa-like, TNF-ALPHA, dif, tnfa, xtnf, tnfsf2, tnf-alpha, Cachectin |
General function | Infliximab is indicate for rheumatoid arthritis, Adult and paediatric Crohn's disease, ulcerative colitis, ankylosing spondylitis and psoriasis. |
Short description | |
Pharmacodynamic properties (Mechanism of action; Source EMA document) | Infliximab is a chimeric human-murine monoclonal antibody that binds with high affinity to both soluble and transmembrane forms of TNFα but not to lymphotoxin α (TNFß). |
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document) | Infliximab inhibits the functional activity of TNFα in a wide variety of in vitro bioassays. Infliximab prevented disease in transgenic mice that develop polyarthritis as a result of constitutive expression of human TNFα and when administered after disease onset, it allowed eroded joints to heal. In vivo, infliximab rapidly forms stable complexes with human TNFα, a process that parallels the loss of TNFα bioactivity. Elevated concentrations of TNFα have been found in the joints of rheumatoid arthritis patients and correlate with elevated disease activity. In rheumatoid arthritis, treatment with infliximab reduced infiltration of inflammatory cells into inflamed areas of the joint as well as expression of molecules mediating cellular adhesion, chemoattraction and tissue degradation. After infliximab treatment, patients exhibited decreased levels of serum interleukin 6 (IL-6) and C-reactive protein (CRP), and increased haemoglobin levels in rheumatoid arthritis patients with reduced haemoglobin levels, compared with baseline. Peripheral blood lymphocytes further showed no significant decrease in number or in proliferative responses to in vitro mitogenic stimulation when compared with untreated patients’ cells. In psoriasis patients, treatment with infliximab resulted in decreases in epidermal inflammation and normalization of keratinocyte differentiation in psoriatic plaques. In psoriatic arthritis, short term treatment with Remicade reduced the number of T-cells and blood vessels in the synovium and psoriatic skin. Histological evaluation of colonic biopsies, obtained before and 4 weeks after administration of infliximab, revealed a substantial reduction in detectable TNFα. Infliximab treatment of Crohn’s disease patients was also associated with a substantial reduction of the commonly elevated serum inflammatory marker, CRP. Total peripheral white blood cell counts were minimally affected in infliximab-treated patients, although changes in lymphocytes, monocytes and neutrophils reflected shifts towards normal ranges. Peripheral blood mononuclear cells (PBMC) from infliximab-treated patients showed undiminished proliferative responsiveness to stimuli compared with untreated patients, and no substantial changes in cytokine production by stimulated PBMC were observed following treatment with infliximab. Analysis of lamina propria mononuclear cells obtained by biopsy of the intestinal mucosa showed that infliximab treatment caused a reduction in the number of cells capable of expressing TNFα and interferonγ. Additional histological studies provided evidence that treatment with infliximab reduces the infiltration of inflammatory cells into affected areas of the intestine and the presence of inflammation markers at these sites. Endoscopic studies of intestinal mucosa have shown evidence of mucosal healing in infliximab-treated patients. |
Original license holder | |
Marketing authorisation numbers | EU/1/99/116/001 - 005 |
Marketing authorisation holder | Janssen Biologics B.V. Einsteinweg 101 2333 CB Leiden The Netherlands |
Name of the manufacturer of the biological active substance | Janssen Biologics B.V. Einsteinweg 101 2333 CB Leiden The Netherlands Janssen Biotech Inc. 200 Great Valley Parkway Malvern Pennsylvania 19355-1307, United States of America |
Name and address of the manufacturer(s) responsible for batch release | Janssen Biologics B.V. Einsteinweg 101 2333 CB Leiden The Netherlands |
Max shelf life | 36 months |
Storage conditions | 2°C – 8°C |
List of excipients | Sucrose Polysorbate 80 Monobasic sodium phosphate Dibasic sodium phosphate |
Do you have any questions about the product, the ordering process or any other detail? Please contact us, we will reply within 24 hours.
At Evidentic, we deal with clinical-grade therapeutic molecules. Think of them as the building blocks for tomorrow’s groundbreaking treatments. These molecules are the active ingredients you’ll find in original drugs prescribed to patients, produced under the strictest quality and safety standards. They’ve also been therapeutically proven through rigorous clinical trials, meaning their effectiveness and safety for treating human diseases have been established. By offering researchers access to these essential tools, we’re fueling the fight for a healthier future.
Unlike some commercially available molecules, Evidentic’s clinical-grade therapeutics aren’t just research possibilities – they’re proven powerhouses! Derived from actual drugs used to treat human diseases, these molecules have already undergone rigorous testing and met the strictest safety and quality standards. This means researchers can focus their energy on groundbreaking discoveries, not questioning the reliability of their tools. With Evidentic, you get the confidence of knowing you’re working with the building blocks for real-world medical advancements.
If you struggle to source clinical-grade biologics you need for your research, Evidentic bridges the gap. We offer royalty-free research consumables (RUO-only) derived from original licensed drugs, giving you access to these critical research tools without the hassle.
But that’s not all. We understand the importance of batch variety in your research. That’s why we’ve built a comprehensive stock library, offering numerous batches of the same active pharmaceutical ingredient (API). This dedication to choice means you can find the exact batch that aligns with your specific research needs.
And because we’re constantly expanding our library, you can be sure we’re actively searching for new batches to add to your research arsenal. With Evidentic, unlock the power of readily available, high-quality research tools and accelerate your scientific breakthroughs.
Evidentic offers access to pharmaceuticals approved by the U.S. FDA (Food and Drug Administration) and/or the EMA (European Medicines Agency). This gives you access to a wider variety of molecules for your research, potentially shortening timelines and boosting the accuracy of your results. Compare EU and US molecules head-to-head, and accelerate your early drug development projects with access to these high-quality research tools. Contact us today to explore the possibilities!
Evidentic’s aliquots from approved pharnaceuticals can be used for analytical, in vitro research, typically executed in early drug development stage of drug discovery programs, like: